Thank you for subscribing!
Next Investors May 06, 2024
Our biotech Investment, Neurotech International (ASX: NTI) just announced additional data from its Rett Syndrome clinical trial today.
Next Investors Oct 09, 2023
Today, our biotech Investment, Emryia (ASX: EMD) has successfully dosed its first patient in a Phase 2b trial using MDMA for the treatment of Post Traumatic Stress Disorder (PTSD).
Next Investors Oct 06, 2023
Our most recent biotech Investment, Neurotech International (ASX:NTI), has just released successful phase I/II trial results for treating a rare childhood neurological disorder called PANDAS/PANS.
Next Investors Sep 18, 2023
We are excited to announce our latest investment in Neurotech International (ASX: NTI), an early-stage biotech targeting rare neurological disorders in children; the company is primed for three major share price catalysts in the form of clinical trial results over the next 6-12 months, echoing a strategic approach similar to Neuren Pharmaceuticals, which experienced a 1,300% share price rise over three years.
Get expert stock analysis direct in your inbox
Wise-Owl Sep 06, 2023
Our investment, BOD Science (ASX: BOD), has successfully demonstrated the statistical efficacy of its 100mg CBD product for treating insomnia in a Phase IIb study. This milestone puts BOD on track to be the first Australian company to offer a CBD-based insomnia treatment over-the-counter.
Wise-Owl Jun 26, 2023
BOD Science (ASX:BOD) has shifted gears from slowly growing revenue, in favour of going for a big blue sky approach to delivering shareholder outcomes. With two near term catalysts on the horizon, could this be the time for BOD?
Next Investors Dec 15, 2022
Our Biotech Pick of the Year, Dimerix Limited (ASX: DXB), has just announced the completion of patient recruitment for the Phase 3 Interim Analysis data. This is a crucial stage in DXB's FSGS clinical trials, helping inch closer to hopefully produce their drug which helps Renal Kidney disease patients.
Next Investors Jun 08, 2022
Yesterday our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), announced an agreement with the Australian Centre for Accelerating Diabetes Innovation to commence a clinical trial on Diabetic Kidney Disease expected Q4 2022.
Finfeed Jun 01, 2022
Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.
Join Our Mailing List
